Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 60

Sort by

Sort Order Select

Journal Articles

Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia

Marlise R. Luskin, Mark Alan Murakami, Julia H. Keating, Yael Flamand, Eric S Winer, Jacqueline S. Garcia, Maximilian Stahl, Richard M. Stone, Martha Wadleigh, Stella Louise Jaeckle, Ella Hagopian, David M. Weinstock, Jessica Liegel, Malgorzata McMasters, Eunice S Wang, Wendy Stock, Daniel J DeAngelo

Blood blood.2024025800.

https://doi.org/10.1182/blood.2024025800

Published: 2024

Includes: Supplemental data

Journal Articles

TP53-Mutated Acute Myeloid Leukemia: How Can We Improve Outcomes?

David A Sallman, Maximilian Stahl

Blood blood.2024024245.

https://doi.org/10.1182/blood.2024024245

Published: 2024

Journal Articles

TP53 mutations and Their Impact on Survival in Patients with Myeloproliferative Neoplasms

Benjamin Rolles, Cilomar Martins De Oliveira Filho, Julia Keating, Marlise R. Luskin, Daniel J. DeAngelo, Coleman Lindsley, Annette S. Kim, Jessica Hem, Chulwoo J. Kim, Lachelle D. Weeks, Mohammed Wazir, Joan How, Anna E. Marneth, Yiwen Liu, Martin J. Aryee, Harrison K. Tsai, Maximilian Stahl, Ann Mullally

Blood (2023) 142 (Supplement 1): 3160.

https://doi.org/10.1182/blood-2023-185024

Published: 2023

Journal Articles

Subunit-Specific Analysis of Cohesin-Mutant Myeloid Malignancies Reveals Distinct Ontogeny and Outcomes

Blood (2023) 142 (Supplement 1): 999.

https://doi.org/10.1182/blood-2023-187519

Published: 2023

Journal Articles

Common Pathways for Acute Myeloid Leukemia Progression in Systemic Mastocytosis with Associated Hematologic Neoplasm

Virginia O. Volpe, Marlise R. Luskin, Maximilian Stahl, Coleman Lindsley, Daniel J. DeAngelo

Blood (2023) 142 (Supplement 1): 6400.

https://doi.org/10.1182/blood-2023-184587

Published: 2023

Journal Articles

Tagraxofusp in Combination with Azacitidine and Venetoclax in Newly Diagnosed CD123+ Acute Myeloid Leukemia, Expansion Cohort of a Phase 1b Multicenter Trial

Blood (2023) 142 (Supplement 1): 4277.

https://doi.org/10.1182/blood-2023-180010

Published: 2023

Journal Articles

Safety and Preliminary Efficacy of DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Guillermo Garcia-Manero, Melissa Ooi, Zhentang Lao, Harinder Gill, Yasmin Abaza, Maximilian Stahl, Tamanna Haque, Amy E. DeZern, Peter L. Greenberg, Marc Pelletier, Arti Singh, Daniel Carreon, Valerie Beaulieu, Janghee Woo

Blood (2023) 142 (Supplement 1): 3250.

https://doi.org/10.1182/blood-2023-174642

Published: 2023

Journal Articles

Myeloid Neoplasia in Patients with Hereditary Hemoglobinopathies and Hemolytic Anemias (HHAs)

Miriam A. Osei, Lauren E. Merz, Kelly S. Chien, Danielle E. Hammond, Coleman Lindsley, Marlise R. Luskin, Maximilian Stahl, Joan How, Mohammed Wazir, Anna E. Marneth, Shai Shimony, Ann Mullally, Daniel J. DeAngelo, Guillermo Garcia-Manero, Maureen Okam Achebe, Benjamin L. Ebert, Lachelle D. Weeks

Blood (2023) 142 (Supplement 1): 2427.

https://doi.org/10.1182/blood-2023-172992

Published: 2023

Journal Articles

Mutations in the RNA Splicing Factors U2AF1 and SRSF2 are Context-Dependent in Myeloproliferative Neoplasms

Swarna Bale, Chulwoo J. Kim, Joan How, Mohammed Wazir, Lachelle D. Weeks, Maximilian Stahl, Marlise R. Luskin, Daniel J. DeAngelo, Coleman Lindsley, Annette S. Kim, Ann Mullally, Anna E. Marneth

Blood (2023) 142 (Supplement 1): 1788.

https://doi.org/10.1182/blood-2023-178657

Published: 2023

Journal Articles

Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Underwent Allogenic Stem Cell Transplantation (HSCT)

Blood (2023) 142 (Supplement 1): 4980.

https://doi.org/10.1182/blood-2023-186578

Published: 2023

Journal Articles

What Is the Optimal Treatment Modality in Molecularly Defined Secondary AML? a Multicenter Cohort Study

Shai Shimony, Jan Philipp Bewersdorf, Rory M. Shallis, Yiwen Liu, Eva Johanna Schaefer, Amer M. Zeidan, Aaron D. Goldberg, Eytan M. Stein, Guido Marcucci, Evan C. Chen, Jorge Ramos, R. Coleman Lindsley, Anthony Selwyn Stein, Daniel J. DeAngelo, Donna S. Neuberg, Richard M Stone, Brian J. Ball, Maximilian Stahl

Blood (2023) 142 (Supplement 1): 1478.

https://doi.org/10.1182/blood-2023-172763

Published: 2023

Journal Articles

Impact of Type of Hypomethylating Agent (HMA) Used on Outcomes of Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) - a Large, Multicenter, Retrospective Analysis

Blood (2023) 142 (Supplement 1): 4613.

https://doi.org/10.1182/blood-2023-178728

Published: 2023

Journal Articles

Cardiovascular Risk Factors Are Common in Myeloproliferative Neoplasms and Portend Worse Survival and Thrombotic Outcomes

Joan How, Orly Leiva, Anna E. Marneth, Baransel Kamaz, Chulwoo J. Kim, Lachelle D. Weeks, Mohammed Wazir, Maximilian Stahl, Daniel J. DeAngelo, R. Coleman Lindsley, Marlise R. Luskin, Gabriela S. Hobbs

Blood (2023) 142 (Supplement 1): 4568.

https://doi.org/10.1182/blood-2023-179324

Published: 2023

Journal Articles

Mini-Hyper-CVD Plus Venetoclax for Treatment of Older Adults with Newly Diagnosed Ph-Negative B-ALL or T-ALL

Marlise R. Luskin, Shai Shimony, Julia Keating, Wendy Stock, Hanno Hock, Jacqueline S. Garcia, Maximilian Stahl, Ilene Galinksy, Rebecca Leonard, Howard Weiner, Yael Flamand, Donna S. Neuberg, Richard M Stone, Anthony G. Letai, Eric S. Winer, Marina Y. Konopleva, Nitin Jain, Daniel J. DeAngelo

Blood (2023) 142 (Supplement 1): 2875.

https://doi.org/10.1182/blood-2023-174269

Published: 2023

Journal Articles

Molecular Ontogeny in AML Is Both Prognostic and Predictive in Patients Treated with Hypomethylating Agents Plus Venetoclax

Shai Shimony, Jacqueline S. Garcia, Julia Keating, Evan C. Chen, Marlise R. Luskin, Maximilian Stahl, Donna S. Neuberg, Daniel J. DeAngelo, Richard M Stone, R. Coleman Lindsley

Blood (2023) 142 (Supplement 1): 977.

https://doi.org/10.1182/blood-2023-173935

Published: 2023

Journal Articles

A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL and Blast Phase CML in Adults

Marlise R. Luskin, Mark Alan Murakami, Julia Keating, Eric S. Winer, Jacqueline S. Garcia, Maximilian Stahl, Martha Wadleigh, Yael Flamand, Donna S. Neuberg, Ilene Galinsky, Rebecca Leonard, Ella Hagopian, Chase M Weizer, Carlin McLanahan, Richard M Stone, Eunice S. Wang, Wendy Stock, Daniel J. DeAngelo

Blood (2023) 142 (Supplement 1): 965.

https://doi.org/10.1182/blood-2023-174246

Published: 2023

Journal Articles

Evaluating Inpatient Care Team Models in Hematology and Oncology Fellowship Programs in the United States

Jessica M. Stempel, Allison J. Li, Alexander B Pine, Valentina Restrepo, Jan Philipp Bewersdorf, Maximilian Stahl, Nikolai A. Podoltsev, Lourdes Mendez, Rory M. Shallis, Deepa Rangachari, Alfred I Lee, Laura C. Michaelis, Amer M. Zeidan

Blood (2023) 142 (Supplement 1): 2319.

https://doi.org/10.1182/blood-2023-187163

Published: 2023

Journal Articles

Intensive Induction Chemotherapy Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in NPM1 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Jan Philipp Bewersdorf, Shai Shimony, Rory M. Shallis, Yiwen Liu, Eva Johanna Schaefer, Amer M. Zeidan, Aaron D. Goldberg, Eytan M. Stein, Guido Marcucci, R. Coleman Lindsley, Evan C. Chen, Jorge Ramos, Anthony Selwyn Stein, Daniel J. DeAngelo, Donna S. Neuberg, Richard M Stone, Brian J. Ball, Maximilian Stahl

Blood (2023) 142 (Supplement 1): 2964.

https://doi.org/10.1182/blood-2023-174285

Published: 2023

Journal Articles

Unlike TET2 and ASXL1 , Co-Occurring DNMT3A Mutations Are Not Associated with Increased Age in JAK2 -Mutant Myeloproliferative Neoplasms (MPNs)

Joan How, Anna E. Marneth, Baransel Kamaz, Chulwoo J. Kim, Donna S. Neuberg, Siyang Ren, Mohammed Wazir, Lachelle D. Weeks, Maximilian Stahl, Daniel J. DeAngelo, R. Coleman Lindsley, Marlise R. Luskin, Sahand Hormoz, Ann Mullally

Blood (2023) 142 (Supplement 1): 4521.

https://doi.org/10.1182/blood-2023-179407

Published: 2023

Journal Articles

Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Were Treated with Hypomethylating Agents (HMA)

Blood (2023) 142 (Supplement 1): 3240.

https://doi.org/10.1182/blood-2023-186340

Published: 2023

NARROW

Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia

TP53-Mutated Acute Myeloid Leukemia: How Can We Improve Outcomes?

TP53 mutations and Their Impact on Survival in Patients with Myeloproliferative Neoplasms

Subunit-Specific Analysis of Cohesin-Mutant Myeloid Malignancies Reveals Distinct Ontogeny and Outcomes

Common Pathways for Acute Myeloid Leukemia Progression in Systemic Mastocytosis with Associated Hematologic Neoplasm

Tagraxofusp in Combination with Azacitidine and Venetoclax in Newly Diagnosed CD123+ Acute Myeloid Leukemia, Expansion Cohort of a Phase 1b Multicenter Trial

Safety and Preliminary Efficacy of DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Myeloid Neoplasia in Patients with Hereditary Hemoglobinopathies and Hemolytic Anemias (HHAs)

Mutations in the RNA Splicing Factors U2AF1 and SRSF2 are Context-Dependent in Myeloproliferative Neoplasms

Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Underwent Allogenic Stem Cell Transplantation (HSCT)

What Is the Optimal Treatment Modality in Molecularly Defined Secondary AML? a Multicenter Cohort Study

Impact of Type of Hypomethylating Agent (HMA) Used on Outcomes of Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) - a Large, Multicenter, Retrospective Analysis

Cardiovascular Risk Factors Are Common in Myeloproliferative Neoplasms and Portend Worse Survival and Thrombotic Outcomes

Mini-Hyper-CVD Plus Venetoclax for Treatment of Older Adults with Newly Diagnosed Ph-Negative B-ALL or T-ALL

Molecular Ontogeny in AML Is Both Prognostic and Predictive in Patients Treated with Hypomethylating Agents Plus Venetoclax

A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL and Blast Phase CML in Adults

Evaluating Inpatient Care Team Models in Hematology and Oncology Fellowship Programs in the United States

Intensive Induction Chemotherapy Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in NPM1 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Unlike TET2 and ASXL1 , Co-Occurring DNMT3A Mutations Are Not Associated with Increased Age in JAK2 -Mutant Myeloproliferative Neoplasms (MPNs)

Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Were Treated with Hypomethylating Agents (HMA)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only